Lataa...
Synergistic effect between erlotinib and MEK inhibitors in KRAS wildtype human pancreatic cancer cells
PURPOSE: The combination of gemcitabine plus erlotinib has shown a small but statistically significant survival advantage when compared to gemcitabine alone in patients with advanced pancreatic cancer. However, the overall survival rate with the erlotinib and gemcitabine combination is still low. In...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2011
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3265169/ https://ncbi.nlm.nih.gov/pubmed/21385921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2214 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|